BVXP.L
Bioventix PLC

Healthcare · Biotechnology · valued as of 2026-11-03 · statements 2025-06-30

Average Intrinsic Value

122.55M USD

Market Cap

117.86M USD

Margin of Safety

3.8%

Intrinsic / Market Ratio

1.04×

Projections, not exact values. Intrinsic Values are projected from each company's past reports. They show which stocks look cheap compared with the others, not exactly what a stock is worth.

How Each Value Is Built

The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.

EPV + Growth

149.18M USD

what the normal year's earnings are worth for ever, plus growth that pays

Profit

87.85M USD

15 years of cash the shareholders can take out, and the equity left at year 15

FCFF

130.63M USD

15 years of cash for shareholders and lenders, less what is owed

Intrinsic Value

122.55M USD

the plain average of the three, uncapped, as the screener averages them

Intrinsic Value

122.55M USD

from the sum above

Market Cap

117.86M USD

the price on the date above times the shares

Intrinsic Value ÷ Market Cap

1.04×

the ratio the screener ranks by; Margin of Safety +3.8% (1 − Market Cap ÷ Intrinsic Value)

Each card below builds one of the three values from the reported years.

Earnings power value plus growth: 149.18M USD
What the normal year's operating profit after tax is worth if it lasts for ever, plus what the new investment adds beyond its cost, less the net debt that comes before the shareholders (or plus the net cash).
①EPV (earnings power value)142.03M USD
+②Net Cash Today7.15M USD
+③Growth Value0 USD
=Value149.18M USD

EPV of the Operations (NOPAT over WACC)

142.03M USD

Net cash today

+7.15M USD

Growth Value

0 USD

Value

149.18M USD

①EPV (earnings power value)

142.03M USD

②Net Cash Today

7.15M USD

③Growth Value

0 USD

Market value

Market Cap117.86M USD

The price on the date above times the shares.

Value vs market

Margin of Safety+21.0%

1 minus the market cap as a share of the value.

Profit value: today's value of the shareholders' equity, from the cash it can pay them (FCFE): 87.85M USD
Fifteen years of free cash flow to equity (FCFE), each brought to today at the cost of equity, plus the equity at year 15 brought to today.
①Present Value of the 15 Years of FCFE77.59M USD
+②Equity at Year 15, Today10.26M USD
=Value87.85M USD
FCFE: the net income left for the shareholders once the business keeps what next year's growth needsEquity reinvestment: the part of the year's net income kept in the business to grow the next year; below zero, capital the business releases to the shareholdersPresent value of the FCFEColoured bars show the FCFE, grey bars the equity reinvestment. With a positive equity reinvestment the two stacked are the year's normalized income; with a negative one the grey is below zero, capital the business releases, and the normalized income is the FCFE plus that negative amount. Shaded, years 6 to 10: the growth rising to its long-run rate and the ROE on new investment falling to the cost of equity. Axes linear.

①Present Value of the 15 Years of FCFE

77.59M USD

②Equity at Year 15, Today

10.26M USD

Market value

Market Cap117.86M USD

The price on the date above times the shares.

Value vs market

Margin of Safety-34.2%

1 minus the market cap as a share of the value.

FCFF value: today's value of the shareholders' equity, from the cash the firm can pay its shareholders and lenders (FCFF): 130.63M USD
Fifteen years of free cash flow to the firm (FCFF), each brought to today at the WACC, plus the invested capital at year 15 brought to today, less the net debt today (or plus the net cash).
①Present Value of the 15 Years of FCFF109.16M USD
+②Invested Capital at Year 15, Today14.32M USD
+③Net Cash Today7.15M USD
=Value130.63M USD
FCFF: the NOPAT left for the shareholders and the lenders once the business reinvests what next year's growth needsReinvestment: the part of the year's NOPAT put back into the business to grow the next year; below zero, capital the business releasesPresent value of the FCFFColoured bars show the FCFF, grey bars the reinvestment. With a positive reinvestment the two stacked are the year's NOPAT; with a negative one the grey is below zero, capital the business releases, and the NOPAT is the FCFF plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROIC on new investment falling to the WACC. Axes linear.

①Present Value of the 15 Years of FCFF

109.16M USD

②Invested Capital at Year 15, Today

14.32M USD

③Net Cash Today

7.15M USD

Market value

Market Cap117.86M USD

The price on the date above times the shares.

Value vs market

Margin of Safety+9.8%

1 minus the market cap as a share of the value.

The Rates and the Capital the Values Read

The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.

WACC: 7.83%
Cost of Equity =Risk-Free Rate 4.50%+Beta 0.56×Market Risk Premium 6.00%= 7.83%

The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.

Tax Rate for WACC =Tax Provision 3.45M USDPretax Income 13.87M USD= 24.88%

The tax the interest saves.

Interest Expense =EBIT 13.83M USD−Pretax Income 13.87M USD= —

The interest the company paid: EBIT is the profit before tax plus the interest.

No interest is read: it needs debt and an EBIT above the profit before tax, the gap between them being the interest. Without it the cost of debt takes the 4% default.

Cost of Debt 4.00% (default): with no debt or no interest read, the 4% default after tax stands for what the lenders are paid a year.

Debt Weight =Total Debt 0 USDMarket Cap + Total Debt 117.86M USD + 0 USD= 0.00%

The part of the capital the lenders put in, at market value.

WACC =Equity Weight 100.00%×Cost of Equity 7.83%+Debt Weight 0.00%×Cost of Debt 4.00%= 7.83%

Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.

Book value and net debt today
Both from the balance sheet of the newest quarter, 2025-12-31.

Total Assets 17.57M USD − Total Liabilities 2.69M USD = Book Value Today 14.88M USD

Total Debt 0 USD − Cash and Short-Term Investments 7.15M USD = Net Debt Today -7.15M USD

The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.

Quality metrics
Read beside the value, never a condition for it: every company is valued, and a filter in the list is the reader's choice.
MetricFrom
Share dilutionShares Today ÷ Shares Two Years Back − 10.1%at most 5%passes5,224,860 / 5,219,656
Accrual quality(Operating Cash Flow − Net Income) ÷ Total Assets-4.3%at least -10.0%passes(9.66M USD − 10.42M USD) ÷ 17.57M USD
Price to bookMarket Cap ÷ Book Value Today7.92×at most 3×does not pass117.86M USD ÷ 14.88M USD
Operating marginOperating Income ÷ Revenue76.8%above 10.0%passes13.83M USD ÷ 18.01M USD
Revenue growthRevenue ÷ Revenue a Year Before − 14.6%above 10.0%does not pass18.01M USD / 17.22M USD
Net cash(Cash − Total Debt) ÷ Market Cap6.1%above -30%passes(7.15M USD − 0 USD) ÷ 117.86M USD
Operating efficiencyOperating Income ÷ Gross Profit84.5%above 25.0%passes13.83M USD ÷ 16.37M USD

Market Data

The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.

Share price

1686.68 GBp

Enterprise value

80.47M GBP

the provider's own figure

EV / EBITDA

8.17×

Price / book

7.97×

the provider's book

Price / earnings

11.95×

Return on equity

66.6%

the provider's figure, not this page's

Profit margin

59.3%

Revenue growth

-8.5%

Analyst target, mean

3903.90 GBp

Analysts

1

opinions in the consensus

Financial Statements

The annual lines the screener holds, year by year, in USD at each period's rate; the figures this valuation read are in its calculation above.

USD2022202320242025
Income statement

Revenue

14.23M16.18M17.22M18.01M

Gross profit

13.37M15.14M16.05M16.37M

Operating income

11.15M12.72M13.45M13.83M

EBITDA

operating income before depreciation and amortisation

11.44M12.88M13.60M13.96M

Pretax income

11.27M12.80M13.42M13.87M

Net income

9.32M10.57M10.25M10.42M

Normalized income

net income without one-off items, as the data provider prints it; Profit's line when printed

9.32M10.57M10.43M10.42M

R&D

-26.91K-31.87K——
Balance sheet, year end

Total assets

15.93M16.77M17.38M17.67M

Total liabilities

1.57M1.54M2.19M1.80M

Shareholders' equity

the equity the parent's shareholders own, as printed, without minority interest; the book value the values read is total assets less total liabilities, in Book Value and Net Debt above

14.36M15.23M15.19M15.86M

Total debt

————

Cash and equivalents

7.44M7.22M7.59M6.98M

Net PP&E

fixed assets after depreciation

843.24K726.98K605.07K555.32K

Working capital

current assets less current liabilities

12.83M13.76M14.05M14.72M
Cash flow

Operating cash flow

9.18M9.85M10.56M9.66M

Capital expenditure

paid out, so below zero

-14.28K-13.36K-20.14K-26.35K

Depreciation and amortisation

174.13K163.18K143.84K127.49K

Free cash flow

operating cash flow plus capital expenditure

9.16M9.84M10.54M9.63M